Across the seven major markets, many drugs have been approved in Q1 2018. According to the GlobalData Drugs & Consensus Forecast database, Gilead Sciences’ Biktarvy (bictegravir + emtricitabine + tenofovir alafenamide) will be the top earner out of the products that received approval in 2018, with Johnson & Johnson’s Erleada (apalutamide) right behind it, through 2024.

Biktarvy is expected to make over $19B globally within the next seven years, and Erleada will make over $8B. This is due to the fact that human immunodeficiency virus (HIV) and prostate cancer treatments will be continuously needed through 2024.

As shown in Figure 1 and Figure 2 below, there is an increase in percentage each year for both Biktarvy and Erleada through 2024, both globally and in the US, with Biktarvy expected to earn more each year.

Many drugs are expected to make over $1B from 2018–2014, including Vertex Pharmaceuticals’ Symdeko (tezacaftor + ivacaftor) and Kyowa Hakko Kirin’s Crysvita (burosumab). As it is only April, it is entirely possible that there could be further approvals of drugs that may make more revenue than Biktarvy and Erleada.

Two drugs that GlobalData expects to be approved in 2018 that may compete with Biktarvy and Erleada are Pfizer’s XTANDI (enzalutamide) for the treatment of prostate cancer and Merck’s doravirine for the treatment of HIV.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Figure 1: Global Drug Consensus Forecast 2018–2024. Credit: GlobalData.

Figure 2: US Drug Consensus Forecast 2018–2024. Credit: GlobalData.